Allakos Inc. (ALLK) Analysts See $-0.23 EPS

November 11, 2018 - By Hazel Jackson

Analysts expect Allakos Inc. (NASDAQ:ALLK) to report $-0.23 EPS on December, 5.After having $-4.17 EPS previously, Allakos Inc.’s analysts see -94.48 % EPS growth. The stock decreased 7.26% or $4.16 during the last trading session, reaching $53.17. About 225,865 shares traded or 28.40% up from the average. Allakos Inc. (NASDAQ:ALLK) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company has market cap of $2.24 billion. The firm is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. It currently has negative earnings.

More notable recent Allakos Inc. (NASDAQ:ALLK) news were published by: which released: “The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie” on November 07, 2018, also with their article: “The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering” published on November 08, 2018, published: “Stocks To Watch: Looking Beyond The Election” on November 03, 2018. More interesting news about Allakos Inc. (NASDAQ:ALLK) were released by: and their article: “The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos …” published on November 06, 2018 as well as‘s news article titled: “Allakos Announces Clinical Update and Third Quarter 2018 Financial Results” with publication date: November 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News